CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 414 filers reported holding CRISPR THERAPEUTICS AG in Q4 2020. The put-call ratio across all filers is 1.10 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $594 | +48.5% | 13,087 | +83.7% | 0.00% | +100.0% |
| Q2 2023 | $400 | +70.2% | 7,123 | +37.1% | 0.00% | 0.0% |
| Q1 2023 | $235 | -100.0% | 5,196 | -51.3% | 0.00% | -66.7% |
| Q3 2022 | $698,000 | +3.7% | 10,677 | +0.5% | 0.00% | 0.0% |
| Q2 2022 | $673,000 | +6.0% | 10,629 | +5.1% | 0.00% | 0.0% |
| Q1 2022 | $635,000 | -19.0% | 10,118 | -2.2% | 0.00% | 0.0% |
| Q4 2021 | $784,000 | -59.4% | 10,348 | -40.1% | 0.00% | -62.5% |
| Q3 2021 | $1,932,000 | -19.1% | 17,262 | +17.1% | 0.01% | -27.3% |
| Q2 2021 | $2,387,000 | +43.8% | 14,743 | +8.2% | 0.01% | +37.5% |
| Q1 2021 | $1,660,000 | +57.3% | 13,625 | +97.7% | 0.01% | +60.0% |
| Q4 2020 | $1,055,000 | +79.1% | 6,893 | -2.2% | 0.01% | +66.7% |
| Q3 2020 | $589,000 | +37.0% | 7,048 | +20.6% | 0.00% | 0.0% |
| Q2 2020 | $430,000 | +91.1% | 5,845 | +10.2% | 0.00% | +50.0% |
| Q1 2020 | $225,000 | -58.3% | 5,304 | -40.1% | 0.00% | -50.0% |
| Q4 2019 | $539,000 | +162.9% | 8,856 | +77.5% | 0.00% | +300.0% |
| Q3 2019 | $205,000 | – | 4,990 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Gilfoyle Management LLC | 150 | $6,376 | 12.96% |
| Versant Venture Management, LLC | 498,558 | $22,629,548 | 12.03% |
| NEA Management Company, LLC | 1,587,854 | $72,072,693 | 5.57% |
| ARK Investment Management | 7,163,118 | $325,133,913 | 2.49% |
| Nikko Asset Management Americas, Inc. | 3,465,470 | $157,263,029 | 1.88% |
| Integral Health Asset Management, LLC | 275,000 | $12,482,250 | 1.73% |
| Merlin Capital, Inc | 9,092 | $412,686 | 1.54% |
| Del-Sette Capital Management, LLC | 33,977 | $1,542,216 | 1.52% |
| Green Alpha Advisors, LLC | 34,880 | $1,583,203 | 1.22% |
| Ikarian Capital, LLC | 2,039 | $9,255,021 | 1.11% |